January 8, 2026
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
Our Mission, Our Passion
To help people not only live longer, but live better
Recognized Explorers,
Remarkable Experience
We have assembled a team of seasoned drug hunters with significant expertise in the discovery and development of small molecule kinase inhibitors to take our programs to greater levels.
Novel Insights,
Precision Therapeutics
We are developing kinase inhibitors that enhance efficacy through better selectivity and combinability, combat resistance, address brain metastases, and improve safety and patient convenience.
Latest News
Recently Published
Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with CML driven by atypical fusion transcripts
67th Annual American Society of Hematology Annual Meeting | December 2025